{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:24:52Z","timestamp":1790691892360,"version":"4.1.0"},"reference-count":94,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2020,6,13]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Following the success of immune checkpoint blockers (ICBs) in different cancer types, a large number of studies are currently investigating ICBs in patients with hepatocellular carcinoma (HCC), alone or in combination with other treatments. Both nivolumab and pembrolizumab, as well as the combination of nivolumab plus ipilimumab have been granted accelerated approval by the United States Food and Drug Administration for sorafenib-pretreated patients. While nivolumab and pembrolizumab both failed to meet their primary endpoints in phase III trials, the combination of atezolizumab plus bevacizumab eventually improved overall and progression-free survival compared with sorafenib in a front-line phase III trial, and thus, will become the new standard of care in this setting. Despite this breakthrough, there are patient populations with certain underlying conditions that may not be ideal candidates for this new treatment either due to safety concerns or potential lack of efficacy. In this review, we discuss the safety of ICBs in patients with pre-existing autoimmune disease, IBD or a history of solid organ transplantation. Moreover, we summarise emerging preclinical and clinical data suggesting that ICBs may be less efficacious in patients with underlying non-alcoholic steatohepatitis or HCCs with activated Wnt\/\u03b2-catenin signalling.<\/jats:p>","DOI":"10.1136\/gutjnl-2020-321702","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T17:18:18Z","timestamp":1596475098000},"page":"204-214","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":209,"title":["Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups"],"prefix":"10.1136","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct04039607","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04102098","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04224636","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"first","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria"},{"name":"Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria"},{"name":"Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology and Nephrology including Centralized Emergency Department (ZAE), Klinikum Klagenfurt am Worthersee, Klagenfurt, K\u00e4rnten, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"2025121223194410000_70.1.204.1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2025121223194410000_70.1.204.2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/apt.14913","article-title":"Review article: systemic treatment of hepatocellular carcinoma","volume":"48","author":"Pinter","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121223194410000_70.1.204.3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121223194410000_70.1.204.4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"2025121223194410000_70.1.204.5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2025121223194410000_70.1.204.6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025121223194410000_70.1.204.7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"2025121223194410000_70.1.204.8","unstructured":". Available: https:\/\/www.cancerresearch.org\/immunotherapy\/timeline-of-progress"},{"key":"2025121223194410000_70.1.204.9","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"2025121223194410000_70.1.204.10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4012","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (PTS) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"37","author":"Yau","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025121223194410000_70.1.204.12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort","volume":"49","author":"Scheiner","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121223194410000_70.1.204.13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.14","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (PTS) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"2025121223194410000_70.1.204.15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies","volume":"39","author":"Datta","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025121223194410000_70.1.204.16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121223194410000_70.1.204.17","doi-asserted-by":"crossref","first-page":"v286","DOI":"10.1093\/annonc\/mdz247.073","article-title":"A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results","volume":"30","author":"Llovet","year":"2019","journal-title":"Ann Oncol"},{"key":"2025121223194410000_70.1.204.18","doi-asserted-by":"crossref","first-page":"viii718","DOI":"10.1093\/annonc\/mdy424.028","article-title":"Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)","volume":"29:","author":"Pishvaian","year":"2018","journal-title":"Ann Oncol"},{"key":"2025121223194410000_70.1.204.19","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121223194410000_70.1.204.20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1148\/radiol.2015142140","article-title":"Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo","volume":"277","author":"Pinter","year":"2015","journal-title":"Radiology"},{"key":"2025121223194410000_70.1.204.21","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.22","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2025121223194410000_70.1.204.23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2025121223194410000_70.1.204.24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2025121223194410000_70.1.204.25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121223194410000_70.1.204.26","doi-asserted-by":"crossref","DOI":"10.1177\/1176935117712520","article-title":"Immune checkpoint inhibition and the prevalence of autoimmune disorders among patients with lung and renal cancer","volume":"16","author":"El-Refai","year":"2017","journal-title":"Cancer Inform"},{"key":"2025121223194410000_70.1.204.27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025121223194410000_70.1.204.28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cld.111","article-title":"Risk factors for hepatocellular carcinoma","volume":"1","author":"Herbst","year":"2012","journal-title":"Clin Liver Dis"},{"key":"2025121223194410000_70.1.204.29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2014.02.008","article-title":"Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis","volume":"12","author":"Zenouzi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121223194410000_70.1.204.30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2017.02.006","article-title":"Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"Tansel","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121223194410000_70.1.204.31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025121223194410000_70.1.204.32","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with Anti-Programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"2025121223194410000_70.1.204.33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025121223194410000_70.1.204.34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025121223194410000_70.1.204.35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","journal-title":"Cancer Immunol Immun"},{"key":"2025121223194410000_70.1.204.36","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2025121223194410000_70.1.204.38","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025121223194410000_70.1.204.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"2025121223194410000_70.1.204.40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"2025121223194410000_70.1.204.41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"2025121223194410000_70.1.204.42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"2025121223194410000_70.1.204.43","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am J Transplant"},{"key":"2025121223194410000_70.1.204.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.026"},{"key":"2025121223194410000_70.1.204.45","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"2025121223194410000_70.1.204.46","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2016.02.034","article-title":"Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction","volume":"64","author":"Shi","year":"2016","journal-title":"J Hepatol"},{"key":"2025121223194410000_70.1.204.47","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients","volume":"6","author":"Munker","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"2025121223194410000_70.1.204.48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025121223194410000_70.1.204.49","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2025121223194410000_70.1.204.50","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"2025121223194410000_70.1.204.51","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2025121223194410000_70.1.204.52","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025121223194410000_70.1.204.53","unstructured":"Highlights of prescribing information . Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125085s0169lbl.pdf"},{"key":"2025121223194410000_70.1.204.54","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2025121223194410000_70.1.204.55","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21545","article-title":"Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease","volume":"17","author":"Coriat","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2025121223194410000_70.1.204.56","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for Gi adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"32","author":"Burger","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2019.37.4_suppl.664","article-title":"Safety of bevacizumab in cancer patients with inflammatory bowel disease","volume":"37","author":"Herrera Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"2025121223194410000_70.1.204.59","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4049\/jimmunol.0802769","article-title":"Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade","volume":"182","author":"Reynoso","year":"2009","journal-title":"J Immunol"},{"key":"2025121223194410000_70.1.204.60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ibd.21845","article-title":"Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis","volume":"18","author":"Ng","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2025121223194410000_70.1.204.61","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/j.gastro.2004.02.004","article-title":"The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells","volume":"126","author":"Nakazawa","year":"2004","journal-title":"Gastroenterology"},{"key":"2025121223194410000_70.1.204.62","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121223194410000_70.1.204.63","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0411-1"},{"key":"2025121223194410000_70.1.204.64","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"2025121223194410000_70.1.204.65","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2025121223194410000_70.1.204.66","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"2025121223194410000_70.1.204.67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/gutjnl-2017-315068","article-title":"Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma","volume":"67","author":"Gerbes","year":"2018","journal-title":"Gut"},{"key":"2025121223194410000_70.1.204.68","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"2025121223194410000_70.1.204.69","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025121223194410000_70.1.204.70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"2025121223194410000_70.1.204.71","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/febs.14209","article-title":"Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes","volume":"285","author":"Ma","year":"2018","journal-title":"Febs J"},{"key":"2025121223194410000_70.1.204.72","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-1728","article-title":"Nonalcoholic steatohepatitis (NASH) impairs treatment of intrahepatic metastases with CD4+ T cell dependent RNA vaccine","volume":"78","author":"Heinrich","year":"2018","journal-title":"Cancer Res"},{"key":"2025121223194410000_70.1.204.73","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0945"},{"key":"2025121223194410000_70.1.204.74","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12029-017-0047-2","article-title":"Bevacuzimab may be less effective in obese metastatic colorectal cancer patients","volume":"50","author":"Arta\u00e7","year":"2019","journal-title":"J Gastrointest Cancer"},{"key":"2025121223194410000_70.1.204.75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.2009.188946","article-title":"Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer","volume":"59","author":"Guiu","year":"2010","journal-title":"Gut"},{"key":"2025121223194410000_70.1.204.76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.03.031","article-title":"Overweight is associated to a better prognosis in metastatic colorectal cancer: a pooled analysis of FFCD trials","volume":"98","author":"Aparicio","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025121223194410000_70.1.204.77","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.dld.2015.07.001","article-title":"Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors","volume":"47","author":"Nault","year":"2015","journal-title":"Dig Liver Dis"},{"key":"2025121223194410000_70.1.204.78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000477578","article-title":"Impact of individual components of the metabolic syndrome on the outcome of patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"36","author":"Labenz","year":"2018","journal-title":"Dig Dis"},{"key":"2025121223194410000_70.1.204.79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1634\/theoncologist.2010-0227","article-title":"Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents","volume":"16","author":"Ladoire","year":"2011","journal-title":"Oncologist"},{"key":"2025121223194410000_70.1.204.80","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1634\/theoncologist.2011-0213","article-title":"Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?","volume":"16","author":"Steffens","year":"2011","journal-title":"Oncologist"},{"key":"2025121223194410000_70.1.204.81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2025121223194410000_70.1.204.82","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"2025121223194410000_70.1.204.83","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2025121223194410000_70.1.204.84","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025121223194410000_70.1.204.85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121223194410000_70.1.204.86","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"2025121223194410000_70.1.204.87","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025121223194410000_70.1.204.88","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"key":"2025121223194410000_70.1.204.89","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1136\/gutjnl-2019-319658","article-title":"Immune checkpoint inhibitors: use them early, combined and instead of TACE?","volume":"69","author":"De Toni","year":"2020","journal-title":"Gut"},{"key":"2025121223194410000_70.1.204.90","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS"},{"key":"2025121223194410000_70.1.204.91","first-page":"1","article-title":"A rare case of pembrolizumab-Induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2025121223194410000_70.1.204.92","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"2025121223194410000_70.1.204.93","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025121223194410000_70.1.204.94","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2020-321702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:20:01Z","timestamp":1765610401000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2020-321702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,9]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/gutjnl-2020-321702"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2020-321702","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]}}}